Director - Equity & Cryptocurrency Product Development
Payal Shah is Director of Equity Research and Product Development at CME Group, based in London. She leads the development of new products in the equity and alternative investment markets, including futures and options contracts on key benchmark indices such as the S&P 500, NASDAQ-100, Dow Jones, Russell, FTSE, Ibovespa, Nikkei 225, and TOPIX indices. Since joining CME Group in 2016, she has been directly involved in the creation of Cryptocurrency Reference Rates, Bitcoin Futures and Options Contracts, and Ether Futures. She also serves on the CME CF Cryptocurrency Oversight Committee.
Prior to CME Group, Shah was an ETF Product Specialist at MSCI, where she held a Vice President-level role from January 2014 to August 2016, focusing on ETFs, delta-one products, smart beta strategies, and ESG investing. Before that, she was in Delta One ETF Sales at Credit Suisse and held an Equity Sales Trader role at Morgan Stanley within the Equity Derivatives Group.

SMD, Global Head of Equities, FX & Alternative Products, CME Group
Tim McCourt is Senior MD and Global Head of Equities, FX and Alternative Products at CME Group, leading its equity index, FX, cryptocurrency and alternative product strategies. Before CME (2013) he ran the Americas index and Delta One book at RBS and spent a decade at JPMorgan. BA Boston College, MBA Wharton.


.png)
.jpeg)



%201.png)






%201.png)
%201.png)


%201.png)



%201.png)


